Mexilitene use in pregnancy.

A. R. Gregg, P. G. Tomich

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Mexilitene, a class 1b antiarrhythmic, was used throughout an entire pregnancy to treat symptomatic premature ventricular contractions in a patient with mitral valve prolapse. Cord blood and maternal serum mexilitene levels at the time of delivery are given. The following conclusions were reached. (1) Mexilitene may have a future in treating pregnant patients with arrhythmias unresponsive to currently approved antiarrhythmic drugs. (2) Evidence to date has shown no adverse affects in infants of mothers breast-feeding while taking mexilitene. (3) Dosages need to be monitored carefully during pregnancy and the postpartum period to ensure that therapeutic drug levels are maintained.

Original languageEnglish (US)
Pages (from-to)33-35
Number of pages3
JournalJournal of perinatology : official journal of the California Perinatal Association
Volume8
Issue number1
StatePublished - Dec 1 1988

Fingerprint

Mothers
Pregnancy
Mitral Valve Prolapse
Ventricular Premature Complexes
Anti-Arrhythmia Agents
Breast Feeding
Fetal Blood
Postpartum Period
Cardiac Arrhythmias
Serum
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

Mexilitene use in pregnancy. / Gregg, A. R.; Tomich, P. G.

In: Journal of perinatology : official journal of the California Perinatal Association, Vol. 8, No. 1, 01.12.1988, p. 33-35.

Research output: Contribution to journalArticle

@article{d4ecd79babff44509096f36862ccb38b,
title = "Mexilitene use in pregnancy.",
abstract = "Mexilitene, a class 1b antiarrhythmic, was used throughout an entire pregnancy to treat symptomatic premature ventricular contractions in a patient with mitral valve prolapse. Cord blood and maternal serum mexilitene levels at the time of delivery are given. The following conclusions were reached. (1) Mexilitene may have a future in treating pregnant patients with arrhythmias unresponsive to currently approved antiarrhythmic drugs. (2) Evidence to date has shown no adverse affects in infants of mothers breast-feeding while taking mexilitene. (3) Dosages need to be monitored carefully during pregnancy and the postpartum period to ensure that therapeutic drug levels are maintained.",
author = "Gregg, {A. R.} and Tomich, {P. G.}",
year = "1988",
month = "12",
day = "1",
language = "English (US)",
volume = "8",
pages = "33--35",
journal = "Journal of Perinatology",
issn = "0743-8346",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Mexilitene use in pregnancy.

AU - Gregg, A. R.

AU - Tomich, P. G.

PY - 1988/12/1

Y1 - 1988/12/1

N2 - Mexilitene, a class 1b antiarrhythmic, was used throughout an entire pregnancy to treat symptomatic premature ventricular contractions in a patient with mitral valve prolapse. Cord blood and maternal serum mexilitene levels at the time of delivery are given. The following conclusions were reached. (1) Mexilitene may have a future in treating pregnant patients with arrhythmias unresponsive to currently approved antiarrhythmic drugs. (2) Evidence to date has shown no adverse affects in infants of mothers breast-feeding while taking mexilitene. (3) Dosages need to be monitored carefully during pregnancy and the postpartum period to ensure that therapeutic drug levels are maintained.

AB - Mexilitene, a class 1b antiarrhythmic, was used throughout an entire pregnancy to treat symptomatic premature ventricular contractions in a patient with mitral valve prolapse. Cord blood and maternal serum mexilitene levels at the time of delivery are given. The following conclusions were reached. (1) Mexilitene may have a future in treating pregnant patients with arrhythmias unresponsive to currently approved antiarrhythmic drugs. (2) Evidence to date has shown no adverse affects in infants of mothers breast-feeding while taking mexilitene. (3) Dosages need to be monitored carefully during pregnancy and the postpartum period to ensure that therapeutic drug levels are maintained.

UR - http://www.scopus.com/inward/record.url?scp=0024272855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024272855&partnerID=8YFLogxK

M3 - Article

C2 - 3236091

AN - SCOPUS:0024272855

VL - 8

SP - 33

EP - 35

JO - Journal of Perinatology

JF - Journal of Perinatology

SN - 0743-8346

IS - 1

ER -